Sign In
Buy LFCR
$4.42
+0.0600 (+1.38%)
At Close: Jul 31, 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud
Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation conce
PHILADELPHIA, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investi
Lifecore Biomedical: The Turnaround Is Just Getting Started
08:50am, Thursday, 01'st Jan 2026
Lifecore Biomedical (LFCR) has completed its turnaround, emerging as a pure-play US-based CDMO with a cleaned-up balance sheet and high operational leverage. LFCR's new capacity is underutilized but a
Philadelphia, Pennsylvania--(Newsfile Corp. - December 30, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation con
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
12:30pm, Wednesday, 24'th Dec 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inve
Lifecore Biomedical to be Added to Nasdaq Biotech Index
07:00am, Thursday, 18'th Dec 2025
CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
07:00am, Wednesday, 17'th Dec 2025
Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 16'th Dec 2025
CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
02:49pm, Sunday, 07'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary d
Lifecore Biomedical to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 11'th Nov 2025
CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript
08:56pm, Thursday, 06'th Nov 2025
Lifecore Biomedical, Inc. ( LFCR ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Josephs - President, CEO & Director Ryan Lake - Executive VP & CFO Conference Call Parti
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update
04:05pm, Thursday, 06'th Nov 2025
-- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025 , Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Custome
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025
04:05pm, Thursday, 30'th Oct 2025
CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
07:00am, Wednesday, 29'th Oct 2025
Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product
